RxDoctor Payments Data

Michael Eaton, MD

Radiation Oncology · Indianapolis, INNPI 1508065913

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,990 of the $11,341 with a category attached, or 88.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among radiation oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,341in general payments, 2019–2025

Across 471 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • Novartis$1K
  • Elekta, Inc.$846
  • Siemens Medical Solutions USA, Inc.$661
  • AstraZeneca$631
  • Astellas Pharma US Inc$488
  • plus $6K from 54 others
$939,053in research payments, 2019–2025

Across 22 payments — averaging $42,684 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$886K
  • Novocure Inc.$28K
  • Eli Lilly$25K

What the payments were for

  • Travel & lodging$9378%
  • Food & beverage$9,99088%
  • Education$4154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck34$1,583
Novartis90$1,244
Elekta, Inc.7$846
Siemens Medical Solutions USA, Inc.6$661
AstraZeneca(2 entities)29$631
Astellas Pharma US Inc17$488
E.r. Squibb & Sons, L.L.C.27$455
Bayer21$412
Daiichi Sankyo Inc.19$364
Exelixis Inc.13$361
Sanofi14$331
Johnson & Johnson10$323
Eisai Inc.17$300
Seagen Inc.11$270
Novocure Inc.5$221
GSK12$198
Bristol Myers Squibb9$192
Lilly USA, LLC8$150
Pharmacyclics LLC, An Abbvie Company9$148
Gilead(2 entities)8$146
AbbVie7$145
Sobi, Inc3$128
Jazz Pharmaceuticals Inc.6$122
Amgen8$112
Genentech USA, Inc.7$111
Sirtex Medical Inc1$111
Pfizer5$89
Takeda Pharmaceuticals U.S.A., Inc.6$86
Regeneron Healthcare Solutions, Inc.3$83
Clovis Oncology, Inc.5$69
Incyte Corporation4$61
Boehringer Ingelheim3$58
Morphosys, US Inc.3$56
Beigene USA, Inc.4$52
Servier Pharmaceuticals LLC3$48
Pharmacosmos Therapeutics Inc.2$43
Blueprint Medicines Corporation2$41
Coherus Oncology, Inc.2$40
Adaptive Biotechnologies Corporation2$35
Taiho Oncology, Inc.2$33
Dova Pharmaceuticals2$32
Verastem, Inc.1$31
CTI Biopharma Corp.2$29
Syndax Pharmaceuticals, Inc.1$27
Verity Pharmaceuticals Inc.1$26
Genmab U.S., Inc.1$24
Progenics Pharmaceuticals, Inc.1$23
Angiodynamics, Inc.1$22
Tersera Therapeutics LLC1$22
Deciphera Pharmaceuticals Inc.1$20
AVEO Pharmaceuticals, Inc.1$19
Mirati Therapeutics, Inc.1$19
GT Medical Technologies, Inc1$18
Legend Biotech USA Inc.1$18
G1 Therapeutics, Inc.1$16
Global Blood Therapeutics, Inc.1$16
EMD Serono, Inc.1$16
Boston Scientific1$16
Portola Pharmaceuticals, LLC1$15
Rigel Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,341 in reported general payments places this provider in the 95th percentile of 116 radiation oncology providers in Indiana.

See all radiation oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$142,510
Medicare patients
293
Services billed
1,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$1,030
Tamsulosin Hcl13$76

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →